By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Caliper Life Sciences today reported a 10 percent decrease in second-quarter revenues, due to divestitures over the past year. However, its ongoing business had a revenue increase of 4 percent year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.